Childhood spinal muscular atrophy: Controversies and challenges

The Lancet Neurology

Volumn 11, Issue 5, 2012, Pages 443-452

  Mercuri, Eugenio ^a   Bertini, Enrico ^b   Iannaccone, Susan T ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN 1;

ARTIFICIAL VENTILATION; CHILDBIRTH; CHILDHOOD DISEASE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; FAMILY COUNSELING; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; HYPOVENTILATION; INCIDENCE; LIFE SUSTAINING TREATMENT; NERVE CONDUCTION; NUTRITION; OSTEOPOROSIS; OUTCOME ASSESSMENT; OXIMETRY; PALLIATIVE THERAPY; PARENTERAL NUTRITION; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FUNCTION; REVIEW; SCOLIOSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SPINAL MUSCULAR ATROPHY; SPINE FUSION; TRACHEOSTOMY; TRANSLATIONAL RESEARCH; VITAL CAPACITY;

CHILD; CHROMOSOME DELETION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEUROLOGIC EXAMINATION; PATIENT CARE TEAM; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; STANDARD OF CARE; SURVIVAL OF MOTOR NEURON 1 PROTEIN;

EID: 84859816485     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70061-3     Document Type: Review

References (98)

1. Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990, 344:540-541.
2. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
3. Munsat TL, Davies KE International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 1992, 2:423-428.
4. Lorson CL, Rindt H, Shababi M Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet 2010, 19:R111-R118.
5. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007, 22:1027-1049.
6. D'Amico A, Mercuri E, Tiziano FD, Bertini E Spinal muscular atrophy. Orphanet J Rare Dis 2011, 6:71.
7. Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007, 69:1931-1936.
8. Boitano LJ Equipment options for cough augmentation, ventilation, and noninvasive interfaces in neuromuscular respiratory management. Pediatrics 2009, 123(suppl 4):S226-S230.
9. Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005, 57:704-712.
10. Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 2011, 68:779-786.
11. Lunn MR, Wang CH Spinal muscular atrophy. Lancet 2008, 371:2120-2133.
12. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002, 70:358-368.
13. Arkblad EL, Darin N, Berg K, et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord 2006, 16:830-838.
14. Cusco I, Lopez E, Soler-Botija C, Jesus Barcelo M, Baiget M, Tizzano EF A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene. Hum Mutat 2003, 22:136-143.
15. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72400 specimens. Eur J Hum Genet 2012, 20:27-32.
16. Su YN, Hung CC, Lin SY, et al. Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study. PLoS One 2011, 6:e17067.
17. Amara A, Adala L, Ben Charfeddine I, et al. Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients. Eur J Paediatr Neurol 2012, 16:167-174.
18. Tiziano FD, Bertini E, Messina S, et al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul Disord 2007, 17:400-403.
19. Schroth MK Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics 2009, 123(suppl 4):S245-S249.
20. Simonds AK Respiratory support for the severely handicapped child with neuromuscular disease: ethics and practicality. Semin Respir Crit Care Med 2007, 28:342-354.
21. Panitch HB The pathophysiology of respiratory impairment in pediatric neuromuscular diseases. Pediatrics 2009, 123(suppl 4):S215-S218.
22. Roper H, Quinlivan R Implementation of "the consensus statement for the standard of care in spinal muscular atrophy" when applied to infants with severe type 1 SMA in the UK. Arch Dis Child 2010, 95:845-849.
23. Rudnik-Schoneborn S, Heller R, Berg C, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 2008, 45:635-638.
24. Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010, 19:4059-4071.
25. Markstrom A, Cohen G, Katz-Salamon M The effect of long term ventilatory support on hemodynamics in children with spinal muscle atrophy (SMA) type II. Sleep Med 2010, 11:201-204.
26. Messina S, Pane M, De Rose P, et al. Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscul Disord 2008, 18:389-393.
27. Chen YS, Shih HH, Chen TH, Kuo CH, Jong YJ Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III. J Pediatr 2012, 160:447-451.
28. Sproule DM, Montes J, Dunaway S, et al. Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. Neuromuscul Disord 2010, 20:448-452.
29. Sproule DM, Montes J, Dunaway SL, et al. Bioelectrical impedance analysis can be a useful screen for excess adiposity in spinal muscular atrophy. J Child Neurol 2010, 25:1348-1354.
30. Sproule DM, Montes J, Montgomery M, et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord 2009, 19:391-396.
31. Tangsrud SE, Carlsen KC, Lund-Petersen I, Carlsen KH Lung function measurements in young children with spinal muscle atrophy; a cross sectional survey on the effect of position and bracing. Arch Dis Child 2001, 84:521-524.
32. Granata C, Merlini L, Magni E, Marini ML, Stagni SB Spinal muscular atrophy: natural history and orthopaedic treatment of scoliosis. Spine (Phila Pa 1976) 1989, 14:760-762.
33. Fujak A, Ingenhorst A, Heuser K, Forst R, Forst J Treatment of scoliosis in intermediate spinal muscular atrophy (SMA type II) in childhood. Ortop Traumatol Rehabil 2005, 7:175-179.
34. Morillon S, Thumerelle C, Cuisset JM, Santos C, Matran R, Deschildre A [Effect of thoracic bracing on lung function in children with neuromuscular disease]. Ann Readapt Med Phys 2007, 50:645-650.
35. Chng SY, Wong YQ, Hui JH, Wong HK, Ong HT, Goh DY Pulmonary function and scoliosis in children with spinal muscular atrophy types II and III. J Paediatr Child Health 2003, 39:673-676.
36. Granata C, Cervellati S, Ballestrazzi A, Corbascio M, Merlini L Spine surgery in spinal muscular atrophy: long-term results. Neuromuscul Disord 1993, 3:207-215.
37. Robinson D, Galasko CS, Delaney C, Williamson JB, Barrie JL Scoliosis and lung function in spinal muscular atrophy. Eur Spine J 1995, 4:268-273.
38. Akbarnia BA, Boachie-Adjei O, Thompson AG, Asher MA Dual growing rod technique for the treatment of progressive early-onset scoliosis: a multicenter study. Spine (Phila Pa 1976) 2005, 30(17 suppl):S46-S57.
39. Emans JB, Ordonez CL, Lee EY, Ciarlo M The treatment of spine and chest wall deformities with fused ribs by expansion thoracostomy and insertion of vertical expandable prosthetic titanium rib: growth of thoracic spine and improvement of lung volumes. Spine (Phila Pa 1976) 2005, 30(17 suppl):S58-S68.
40. Hell AK, Campbell RM, Hefti F The vertical expandable prosthetic titanium rib implant for the treatment of thoracic insufficiency syndrome associated with congenital and neuromuscular scoliosis in young children. J Pediatr Orthop B 2005, 14:287-293.
41. Thompson GH Growing rod techniques in early-onset scoliosis. J Pediatr Orthop 2007, 27:354-361.
42. Chandran S, McCarthy J, Noonan K, Mann D, Nemeth B, Guiliani T Early treatment of scoliosis with growing rods in children with severe spinal muscular atrophy: a preliminary report. J Pediatr Orthop 2011, 31:450-454.
43. McElroy MJ, Shaner AC, Crawford TO, et al. Growing rods for scoliosis in spinal muscular atrophy: structural effects, complications, and hospital stays. Spine (Phila Pa 1976) 2011, 36:1305-1311.
44. Kinali M, Banks LM, Mercuri E, Manzur AY, Muntoni F Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics 2004, 35:325-328.
45. Khatri IA, Chaudhry US, Seikaly MG, Browne RH, Iannaccone ST Low bone mineral density in spinal muscular atrophy. J Clin Neuromuscul Dis 2008, 10:11-17.
46. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009, 4:e5268.
47. Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, Reddy SV Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. J Pathol 2009, 219:52-60.
48. Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 2001, 45:174-181.
49. Russman BS, Buncher CR, White M, Samaha FJ, Iannaccone ST Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology 1996, 47:973-976.
50. Crowley R, Wolfe I, Lock K, McKee M Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child 2011, 96:548-553.
51. Rudnik-Schoneborn S, Zerres K, Ignatius J, Rietschel M Pregnancy and spinal muscular atrophy. J Neurol 1992, 239:26-30.
52. Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004, 14:130-135.
53. Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68:51-55.
54. Pane M, Staccioli S, Messina S, et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008, 18:536-540.
55. Tiziano FD, Lomastro R, Pinto AM, et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet; 47: 856-58.
56. Kissel JT, Scott CB, Reyna SP, et al. SMA CARNIVAL Trial Part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One; 6: e21296.
57. Miller RG, Moore DH, Dronsky V, et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001, 191:127-131.
58. Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNIVAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010, 5:e12140.
59. Kinali M, Mercuri E, Main M, et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609-610.
60. Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 2003, 18:537-541.
61. Bertini E, Burghes A, Bushby K, et al. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscul Disord 2005, 15:802-816.
62. Lewelt A, Newcomb TM, Swoboda KJ New therapeutic approaches to spinal muscular atrophy. Curr Neurol Neurosci Rep 2012, 12:42-53.
63. Pruss RM, Giraudon-Paoli M, Morozova S, Berna P, Abitbol JL, Bordet T Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development. Future Med Chem 2010, 2:1429-1440.
64. Shababi M, Mattis VB, Lorson CL Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. Drug News Perspect 2010, 23:475-482.
65. Mercuri E, Mayhew A, Muntoni F, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th-13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June-1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 2008, 18:894-903.
66. Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R, Rowland LP Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 2005, 65:1352-1357.
67. Swoboda KJ, Kissel JT, Crawford TO, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol 2007, 22:957-966.
68. Kaufmann P, Iannaccone ST Clinical trials in spinal muscular atrophy. Phys Med Rehabil Clin N Am 2008, 19:653-660.
69. Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 2011, 68:779-786.
70. Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord 2006, 16:93-98.
71. Merlini L, Bertini E, Minetti C, et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve 2004, 29:548-552.
72. Berard C, Fermanian J, Payan C Outcome measure for SMA II and III patients. Neuromuscul Disord 2008, 18:593-594.
73. Berard C, Payan C, Hodgkinson I, Fermanian J A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005, 15:463-470.
74. Nelson L, Owens H, Hynan LS, Iannaccone ST The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 2006, 16:374-380.
75. Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther 2011, 23:322-326.
76. Finkel RS, Hynan LS, Glanzman AM, et al. The test of infant motor performance: reliability in spinal muscular atrophy type I. Pediatr Phys Ther 2008, 20:242-246.
77. Main M, Kairon H, Mercuri E, Muntoni F The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003, 7:155-159.
78. Mazzone E, Bianco F, Martinelli D, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 2011, 21:406-412.
79. O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 2007, 17:693-697.
80. Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol 2011, 26:1499-1507.
81. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006, 16:417-426.
82. Krosschell KJ, Scott CB, Maczulski JA, Lewelt AJ, Reyna SP, Swoboda KJ Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve 2011, 44:246-251.
83. Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 2010, 74:833-838.
84. Steffensen BF, Lyager S, Werge B, Rahbek J, Mattsson E Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol 2002, 44:623-632.
85. Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord 2009, 19:805-812.
86. Rudnik-Schoneborn S, Berg C, Zerres K, et al. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet 2009, 76:168-178.
87. Iannaccone ST, Hynan LS Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003, 60:1130-1136.
88. Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord; 20: 155-61.
89. Krosschell KJ, Scott CB, Maczulski JA, Lewelt AJ, Reyna SP, Swoboda KJ Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve 2011, 44:246-251.
90. Bromberg MB, Swoboda KJ Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 2002, 25:445-447.
91. Bromberg MB, Swoboda KJ, Lawson VH Counting motor units in chronic motor neuropathies. Exp Neurol 2003, 184(suppl 1):S53-S57.
92. Lewelt A, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010, 42:703-708.
93. Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011, 53:535-542.
94. Simard LR, Belanger MC, Morissette S, Wride M, Prior TW, Swoboda KJ Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 2007, 68:451-456.
95. Tiziano FD, Neri G, Brahe C Biomarkers in rare disorders: the experience with spinal muscular atrophy. Int J Mol Sci 2010, 12:24-38.
96. Tiziano FD, Pinto AM, Fiori S, et al. SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet 2010, 18:52-58.
97. Liss J, Bruszczynska A, Lukaszuk K [Preimplantation genetic diagnosis in prevention of genetic diseases-diagnostic of spinal muscular atrophy (SMA)]. Ginekol Pol 2010, 81:918-921. (in Polish).
98. Howard HC, Avard D, Borry P Are the kids really alright? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms?. Eur J Hum Genet 2011, 19:1122. 16.